What the research shows
- 25.0% average weight loss in 80 weeks
- 1.94% average HbA1c drop in 40 weeks
- 82.4% average liver-fat reduction in 24 weeks
Published study results for the compound, not results from this product. For research use only.
Retatrutide is an investigational single-molecule agonist of the GIP, GLP-1 and glucagon receptors, studied in controlled clinical research. This separate 3mL Genovare pen is labelled 60mg and is not presented as sponsor-supplied trial material or an authorised medicine. No batch-specific independent report is linked, so sequence, identity, quantity and purity are unverified.
- Pack Size
- 3mL
- Product details
- Genovare Catalogue
- Pre-Filled Pen
- Premixed Aqueous
- Storage Guidance
- Follow Package Label
- 1 pre-filled Genovare research pen
- 3 pen needles
- Genovare retail packaging
Genovare Pre-Filled Pen Premixed Aqueous
SpecsRetatrutide 60mg AQ Pen
Triple-receptor agonist tested in phase 3 trials
AED 1,750 / pen
Choose your bundle
Minimum order is AED 400
25% off orders of AED 700+ with code KV25 at checkout
Order before 4 PM for same-day Dubai delivery.
UAE delivery: AED 50 below AED 1,000; free from AED 1,000
- Sold by
- Remy Research
- Brand
- Genovare
- Manufacturer
- Genovare
- Tested by
- Independent testing not supplied
Ships from Dubai
Technical Specifications
| Manufacturer | Genovare |
|---|---|
| Compound | Retatrutide |
| Catalogue strength | 60 mg |
| Fill volume | 3mL |
| Format | Aqueous pre-filled pen |
| Pack size | 1 pen with 3 needles |
| Independent testing | Not supplied |